Atossa Therapeutics Shows (Z)-Endoxifen's Potential in ESR1-Mutant Breast Cancer
Event summary
- Atossa Therapeutics presented two abstracts at ASCO 2026 highlighting (Z)-endoxifen's activity across ESR1 mutations in breast cancer.
- Preclinical data showed robust ER inhibition across clinically relevant ESR1 mutations, including D538G, Y537N, and Y537S.
- The EVANGELINE Phase 2 trial is evaluating (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal women with ER+/HER2- breast cancer.
- ASCO 2026 is being held from May 29 to June 2, 2026, in Chicago, IL.
The big picture
Atossa Therapeutics is advancing (Z)-endoxifen as a potential treatment for ER-positive breast cancer, particularly in ESR1-mutant cases where resistance to standard therapies is common. The ongoing EVANGELINE trial and preclinical data presented at ASCO 2026 underscore the company's focus on addressing unmet needs in oncology. The success of (Z)-endoxifen could position Atossa as a key player in the evolving landscape of endocrine therapies for breast cancer.
What we're watching
- Clinical Efficacy
- Whether (Z)-endoxifen can sustain robust ER inhibition in ESR1-mutant settings compared to existing SERDs.
- Regulatory Pathway
- The pace at which Atossa can advance (Z)-endoxifen through clinical trials and potential regulatory approvals.
- Market Differentiation
- How (Z)-endoxifen's distinct mechanism of action positions it against competitors like elacestrant and imlunestrant.
Related topics